So, there's this company called AbbVie that makes medicines. People who buy and sell parts of the company called "options" are making guesses about how the company will do in the future. Sometimes they are right and make money, sometimes they are wrong and lose money. In this article, they talk about how some people are guessing that the price of AbbVie's medicine will go down, and others are guessing it will go up. They also talk about what some experts think about the company and what might happen to its price in the future. Read from source...

1. The article's headline is misleading. The article itself does not dive deep into AbbVie's options trading, nor does it provide significant insights into market sentiment. 2. The options activities highlighted in the article are presented with no contextual analysis. The bullish/bearish percentages are meaningless without an explanation of how they were calculated. 3. The analysis of AbbVie's market position is not thorough, only mentioning the trading volume and RSI values briefly. 4. Expert opinions are presented in a manner that is not informative or useful. There is no analysis of the reasons behind these target prices or any explanation of the factors considered. 5. The tone of the article is overly speculative and lacks rigorous analysis or substantial evidence to support the claims made. Overall, this article seems to be primarily focused on generating clicks and promoting Benzinga Pro services rather than providing valuable, well-researched insights.

Bearish. Investors seem to adopt a bearish approach towards AbbVie, indicated by substantial options trading activities, with majority leaning towards bearish sentiment. The company's trading volume and current RSI values also suggest that the stock may be approaching overbought.

1. AbbVie (ABBV) is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

2. With a trading volume of 2,078,162, the price of ABBV is up by 0.01%, reaching $195.42. Current RSI values indicate that the stock may be approaching overbought.

3. Based on volume and open interest, major market movers are focusing on a price band between $155.0 and $210.0 for AbbVie, spanning the last three months.

4. The general mood among heavyweight investors is divided, with 22% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $245,058, and 3 are calls, amounting to $384,516.

5. Expert opinions on AbbVie include an average target price of $209.0. Morgan Stanley analyst rates AbbVie as Overweight with a target price of $218, while Cantor Fitzgerald analyst downgraded its rating to Overweight, setting a price target of $200. Piper Sandler analyst continues to hold a Overweight rating for AbbVie, targeting a price of $209.

6. Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics.

7. Market players shouldn't ignore the bearish approach of deep-pocketed investors towards AbbVie. Such a substantial move in ABBV usually suggests something big is about to happen.

8. Based on the options trading surrounding AbbVie, traders should keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.

Risks:

1. The options trading activities for AbbVie are out of the ordinary, indicating that they may be associated with significant market movements that could potentially impact the price of the underlying shares.

2. The general mood among heavyweight investors is divided, suggesting uncertainty in the market.

3. Trading options involves greater risks as well as potential for higher profits. Traders must be diligent in their education, trade adjustments, indicators, and market awareness to mitigate these risks.

4. The stock may be approaching overbought, according to RSI values, indicating possible risks for traders.

5. Investors should always conduct their own due diligence before making any investment decisions, taking into account the risks and benefits of potential investments, and always be aware of market conditions.

### Key Takeaways:

1. AbbVie